Vical Inc (VICL): R Gordon Douglas , director of Vical Inc purchased 10,078 shares on Jun 6, 2016. The Insider buying transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were purchased at $4.41 per share for a total value of $44,443.98 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 6, 2016, Gary A Lyons (director) purchased 7,078 shares at $4.39 per share price.On Mar 17, 2016, Lawrence Russell Smith (VP, Vaccine Research) sold 8,750 shares at $0.41 per share price.Also, On Feb 22, 2016, Anthony Alan Ramos (VP, Chief Accounting Officer) sold 7,500 shares at $0.33 per share price.On Jan 13, 2016, Vijay B Samant (President & CEO) sold 59,737 shares at $0.35 per share price.
Shares of Vical Incorporated (VICL) ended Tuesday, Jun 7, 2016 session in red amid volatile trading. The shares closed down -0.06 points or -1.36% at $4.36 with 60,825 shares getting traded. Post opening the session at $4.42, the shares hit an intraday low of $4.35 and an intraday high of $4.43 and the price vacillated in this range throughout the day. The company has a market cap of $40 M and the number of outstanding shares has been calculated to be 92,01,950 shares. The 52-week high of Vical Incorporated is $15.5 and the 52-week low is $2.808.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent or partnered development programs in the areas of infectious disease consisted of: Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial using its Vaxfectin formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2) a cause of recurrent genital herpes and a completed preclinical program with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent CMV infection before and during pregnancy.